Stocks and InvestingStocks and Investing
Tue, February 15, 2022
Mon, February 14, 2022
Fri, February 11, 2022
Thu, February 10, 2022
Wed, February 9, 2022

Andrew Fein Upgraded (ACAD) to Strong Buy and Increased Target to $36 on, Feb 9th, 2022


Published on 2024-10-27 19:37:07 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Increased Target from $18 to $36 on, Feb 9th, 2022.

Andrew has made no other calls on ACAD in the last 4 months.



There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 7 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $32 on, Tuesday, December 21st, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
  • Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021


These are the ratings of the 3 analyists that currently disagree with Andrew


  • Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021
  • Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Tuesday, December 21st, 2021